CliffBio
small molecule

REGADENOSON

REGADENOSON

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameREGADENOSON
Active ingredientREGADENOSON
Strength0.4MG/5ML (0.08MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalApril 2022
Marketing statusRX

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.